Live Event Content · Yuichiro Miyake, MD - Best of the Best in Pediatric Surgery 2024
Follow
Video7 min·Published Feb 2024Older

Yuichiro Miyake, MD - Best of the Best in Pediatric Surgery 2024

With Dr. Yuichiro Miyake

Chapter 1 of 3 · Fundamentals

Introduction

Introduction to presentation on nanoparticle drug delivery for CDH

Try
Intelligent Search· scoped to congenital diaphragmatic hernia · not medical adviceSearch the whole library →
Only a few other public items share this expert — go deeper there →
What the experts said18 expert statements
CDH patients present with a hole in the diaphragm and abnormal lung development resulting in lung hypoplasia and persistent pulmonary hypertension
ClinicalYuichiro Miyake
The incidence of CDH is 1 in 2000 to 5000 live births
EpidemiologicalYuichiro Miyake
About 150 CDH babies are born every day in the world
EpidemiologicalYuichiro Miyake
About 50 CDH babies die every day
EpidemiologicalYuichiro Miyake
Fetoscopic endoluminal tracheal occlusion (FETO) is currently performed to increase survival rate of CDH babies
ClinicalYuichiro Miyake
In a randomized controlled trial, FETO improved the survival rate for severe CDH from 15% to 40%
ClinicalYuichiro Miyake
Chitosan nanoparticles possess the ability to encapsulate various therapeutic substances
ClinicalYuichiro Miyake
Combining FETO with nanoparticle-based drug delivery could potentially lead to better outcomes for CDH babies
OpinionYuichiro Miyake
A microinjector was designed based on a microinsemination device to investigate combination of FETO with drug administration
ClinicalYuichiro Miyake
Rat fetuses were removed on embryonic day 18 for the lung explant model
ClinicalYuichiro Miyake
Nanoparticles were injected into the trachea and the trachea was tied with surgical suture to replicate the FETO model
ClinicalYuichiro Miyake
An IgG antibody selected to target pulmonary tissue was used to functionalize the nanoparticles
ClinicalYuichiro Miyake
IgG nanoparticles exhibited superior uptake into the lungs compared to bare nanoparticles
ClinicalYuichiro Miyake
The relative number of nanoparticles to DAPI was about 2.5-fold higher in the IgG nanoparticles group compared to bare nanoparticles
ClinicalYuichiro Miyake
Active caspase-3 protein abundance was not significantly different among control, bare nanoparticles, and IgG nanoparticles groups
ClinicalYuichiro Miyake
IL-6 protein abundance was not significantly different among control, bare nanoparticles, and IgG nanoparticles groups
ClinicalYuichiro Miyake
Lungs were dissected from rat pups, nanoparticles injected, trachea tied, and cultured for 2-3 days before analysis
ClinicalYuichiro Miyake
The next step involves encapsulating therapeutic agents in chitosan nanoparticles and testing whether they improve lung development in the explant model
OpinionYuichiro Miyake